Shares of ABIVAX Société Anonyme (NASDAQ:ABVX – Get Free Report) have received a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $38.67.
Several equities analysts recently weighed in on ABVX shares. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th.
View Our Latest Stock Analysis on ABIVAX Société Anonyme
Institutional Inflows and Outflows
ABIVAX Société Anonyme Stock Performance
Shares of NASDAQ:ABVX opened at $5.94 on Friday. ABIVAX Société Anonyme has a 52-week low of $5.50 and a 52-week high of $17.02. The stock’s fifty day simple moving average is $6.72 and its 200-day simple moving average is $8.70.
ABIVAX Société Anonyme Company Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
See Also
- Five stocks we like better than ABIVAX Société Anonyme
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- How to Build the Ultimate Everything ETF Portfolio
- 3 Warren Buffett Stocks to Buy Now
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Stock Dividend Cuts Happen Are You Ready?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for ABIVAX Société Anonyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIVAX Société Anonyme and related companies with MarketBeat.com's FREE daily email newsletter.